Fuder H
Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany.
J Ocul Pharmacol. 1994 Spring;10(1):109-23. doi: 10.1089/jop.1994.10.109.
The iris is innervated by nerves of the sympathetic, parasympathetic, and sensory nervous systems. The terminal nerve fibres are endowed with prejunctional receptors which modulate neurotransmitter release. Activation or blockade of prejunctional receptors by drugs may have an influence on iris smooth muscle tone. Several findings are in favour of the hypothesis that prejunctional receptors may be involved in regulation of iris smooth muscle tone and/or pathophysiological events. (i). Release of acetylcholine from parasympathetic nerves of guinea-pig iris sphincter evoked by electrical stimulation is subject to autoinhibition via prejunctional M2 muscarinic receptors, and the release can be enhanced by M2 selective antagonists such as methoctramine or gallamine. Concomitantly with the increased neurotransmitter release, the sphincter contraction is enhanced in the presence of M2 antagonists, since the postjunctional muscarinic receptors (presumably M3, or at least not M2) are not simultaneously blocked. Unlike the non-selective blocker atropine, M2 antagonists are not expected to cause mydriasis but rather miosis. (ii). Sensory nerves are involved in pathophysiological events following ocular irritation. Release of substance P and/or neurokinin A from sensory nerves of rabbit iris is followed by a non-adrenergic-non-cholinergic iris sphincter contraction (mediated by NK1 and NK3 receptors) which can be used to estimate sensory neurotransmitter release. Exocytotic release of the sensory neurotransmitters is inhibited by activation of alpha 2B-adrenoceptors and probably also via putative prejunctional imidazoline receptors. Alpha-adrenoceptors are stimulated by oxymetazoline and other imidazoline derivatives (which are agonists at imidazoline receptors) leading to a reduction of sensory neurotransmitter release, as evident from a decrease in evoked sphincter contraction. Imidazolines in eye drops may not only cause relief in ocular inflammation due to postjunctional vasoconstriction but also possibly due to a prejunctional effect, a reduction of sensory neurotransmitter release. Reinforcement of inflammation due to release of sensory neurotransmitters may thus be prevented.
虹膜由交感神经系统、副交感神经系统和感觉神经系统的神经支配。终末神经纤维具有调节神经递质释放的突触前受体。药物对突触前受体的激活或阻断可能会影响虹膜平滑肌张力。多项研究结果支持这样一种假说,即突触前受体可能参与虹膜平滑肌张力的调节和/或病理生理过程。(i). 豚鼠虹膜括约肌副交感神经电刺激诱发的乙酰胆碱释放可通过突触前M2毒蕈碱受体进行自身抑制,而M2选择性拮抗剂如美索曲明或加拉明可增强其释放。伴随着神经递质释放的增加,在M2拮抗剂存在的情况下,括约肌收缩增强,因为突触后毒蕈碱受体(可能是M3,或至少不是M2)没有同时被阻断。与非选择性阻滞剂阿托品不同,M2拮抗剂预计不会导致散瞳,而是会导致缩瞳。(ii). 感觉神经参与眼刺激后的病理生理过程。兔虹膜感觉神经释放P物质和/或神经激肽A后,会出现非肾上腺素能非胆碱能虹膜括约肌收缩(由NK1和NK3受体介导),可用于估计感觉神经递质释放。感觉神经递质的胞吐释放可通过α2B肾上腺素能受体的激活以及可能还通过假定的突触前咪唑啉受体受到抑制。α肾上腺素能受体受到氧甲唑啉和其他咪唑啉衍生物(它们是咪唑啉受体激动剂)的刺激,导致感觉神经递质释放减少,这从诱发的括约肌收缩减少中可以明显看出。滴眼液中的咪唑啉不仅可能由于突触后血管收缩而缓解眼部炎症,还可能由于突触前效应,即感觉神经递质释放减少。因此,可以防止由于感觉神经递质释放而导致的炎症加剧。